期刊
ORTHOPAEDICS & TRAUMATOLOGY-SURGERY & RESEARCH
卷 107, 期 1, 页码 -出版社
ELSEVIER MASSON, CORP OFF
DOI: 10.1016/j.otsr.2020.102756
关键词
Osteoarthritis of the shoulder in under-50 year-olds; PRP; Viscosupplementation; Hemiarthroplasty; Pyrocarbon; Total shoulder arthroplasty; Glenoid wear
资金
- Ramsay-GDS research and teaching department
For patients under 50 with shoulder osteoarthritis, non-operative treatments like PRP, viscosupplementation and arthroscopy can delay shoulder replacement surgery, with anatomic total shoulder arthroplasty being the preferred solution after other options fail. The most negative factor is ER1 restriction.
Introduction: Osteoarthritis (OA) of the shoulder in under-50 year-olds is rare, and treatment is delicate. Shoulder replacement incurs frequent long-term risk of progression and a high revision rate, making it unsuited to young active patients. The aim of the present study was to determine the epidemiology of shoulder OA in under-50 year-olds and to assess the clinical results of the various treatment options. Hypothesis: The main study hypothesis was that well-conducted non-operative treatment can allow shoulder replacement to be postponed. The secondary hypothesis was that anatomic total shoulder arthroplasty (TSA) is the treatment of choice when other options fail. Materials and methods: A multicenter retrospective study included primary (POA) and post-instability osteoarthritis (PIOA) in patients aged <= 50 years at symptom onset. Exclusion criteria comprised post traumatic OA, rheumatoid arthritis and necrosis. Two hundred and sixty-six patients for 273 shoulders were included from 13 shoulder surgery centers: 2 types of non-operative treatment (28 by platelet-rich plasma [PRP] and 88 by viscosupplementation), 73 arthroscopies, and 150 implantations (62 humeral hemiarthroplasties [HA], comprising 10 hemi-metal, 24 hemi-pyrocarbon and 28 hemi-resurfacing; 77 anatomic total prostheses, and 11 reverse prostheses). Minimum follow-up was 12 months for non operative treatment and 24 months for arthroplasty (some patients having both). Endpoints comprised Constant score, Subjective Shoulder Value (SSV) and number of complications/revision procedures. Results: Mean age at treatment was 43 years (range, 23-65 years), with 75% male predominance. Symptom onset was earlier in PIOA than in POA: 36 vs. 39 years (range, 20-50 years). PRP and viscosupplementation postponed implantation by a mean 3.5 years in 86% of cases, as did arthroscopy in 56%. ER1 restriction was the most negative factor. At 74 months' follow-up for HA and 95 months for TSA, mean Constant score was significantly lower for HA (56 vs. 67; p = 0.004), with higher rates of complications (31% vs. 11%) and implant exchange (13% vs. 9%). Discussion/conclusion: PRP, viscosupplementation and arthroscopy allow implantation to be postponed until the shoulder becomes stiff and painful. In case of failure, TSA is the most effective solution in the medium-term. (C) 2020 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据